Correction to: Evaluation of Cardiovascular Disease Risk in HIV ‑1–Infected Patients Treated with Darunavir
In the original publication of the article, Table 2 has been published incorrectly. (Source: Drugs in R&D)
Source: Drugs in R&D - August 6, 2018 Category: Drugs & Pharmacology Source Type: research
Comments on: “In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea”
(Source: Drugs in R&D)
Source: Drugs in R&D - August 4, 2018 Category: Drugs & Pharmacology Source Type: research
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
ConclusionsFindings from this study indicate that intravenous golimumab is effective in managing RA in a population of patients switching directly from infliximab (mean last dose 7.4 mg/kg). (Source: Drugs in R&D)
Source: Drugs in R&D - July 28, 2018 Category: Drugs & Pharmacology Source Type: research
Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers
ConclusionsThis compartmental modelling analysis suggests ELF exposures of both ceftazidime and avibactam exceed levels required for efficacy in plasma. (Source: Drugs in R&D)
Source: Drugs in R&D - July 27, 2018 Category: Drugs & Pharmacology Source Type: research
Evaluation of Cardiovascular Disease Risk in HIV-1 –Infected Patients Treated with Darunavir
ConclusionsThis comprehensive review of Janssen-sponsored clinical trial, post-marketing, and epidemiological data does not suggest that CVD should be considered an important risk for users of darunavir. (Source: Drugs in R&D)
Source: Drugs in R&D - July 10, 2018 Category: Drugs & Pharmacology Source Type: research
Correction to: Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication
In the Original Publication. (Source: Drugs in R&D)
Source: Drugs in R&D - July 9, 2018 Category: Drugs & Pharmacology Source Type: research
Octreotide Use in Neonates: A Case Series
ConclusionOctreotide was used safely as an adjunctive therapy for the treatment of chylothorax and chylous ascites in neonates. However, larger prospective controlled trials are required to establish the optimal dose, time of initiation, duration and efficacy of octreotide therapy in neonates. (Source: Drugs in R&D)
Source: Drugs in R&D - June 15, 2018 Category: Drugs & Pharmacology Source Type: research
Co-crystal of Tramadol –Celecoxib in Patients with Moderate to Severe Acute Post-surgical Oral Pain: A Dose-Finding, Randomised, Double-Blind, Placebo- and Active-Controlled, Multicentre, Phase II Trial
ConclusionSignificant improvement in the benefit –risk ratio was observed for CTC (doses ≥ 100 mg) over tramadol and placebo in the treatment of acute pain following oral surgery.FundingLaboratorios del Dr. Esteve, S.A.U. (Source: Drugs in R&D)
Source: Drugs in R&D - June 1, 2018 Category: Drugs & Pharmacology Source Type: research
The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
AbstractApomorphine is now recognized as the oldest antiparkinsonian drug on the market. Though still underused, it is increasingly prescribed in Europe for patients with advanced Parkinson ’s disease (PD) with motor fluctuations. However, its history is far from being limited to movement disorders. This paper traces the history of apomorphine, from its earliest empirical use, to its synthesis, pharmacological development, and numerous indications in human and veterinary medicine, in light of its most recent uses and newest challenges. From shamanic rituals in ancient Egypt and Mesoamerica, to the treatment of erectile d...
Source: Drugs in R&D - June 1, 2018 Category: Drugs & Pharmacology Source Type: research
Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
ConclusionHepatic status did not significantly impact systemic exposure of fasiglifam in this study, in fact, a decrease was observed, suggesting no dose reduction would be required for patients with hepatic impairment. (Source: Drugs in R&D)
Source: Drugs in R&D - June 1, 2018 Category: Drugs & Pharmacology Source Type: research
Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers
ConclusionsAZD5069 demonstrated predictive linear pharmacokinetics with low intra- and moderate inter-subject variability and no major influences from ethnicity, age, food or formulation. Half-life data indicated suitability for twice-daily dosing.Clinicaltrials.gov identifiersNCT00953888, NCT01051505, NCT01083238, NCT01100047, NCT01332903, NCT01480739, NCT01735240, NCT01989520. (Source: Drugs in R&D)
Source: Drugs in R&D - June 1, 2018 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of Sublingual Fentanyl Tablets in Breakthrough Cancer Pain Management According to Cancer Stage and Background Opioid Medication
ConclusionsExploratory subgroup analyses show the efficacy and safety of SFTs for the treatment of breakthrough pain in patients with cancer, regardless of their cancer stage and background opioid medication. (Source: Drugs in R&D)
Source: Drugs in R&D - June 1, 2018 Category: Drugs & Pharmacology Source Type: research
A Phase I Study of the Pharmacokinetics and Pharmacodynamics of Intranasal Doxylamine in Subjects with Chronic Intermittent Sleep Impairment
ConclusionThe nasal spray did not increase doxylamine absorption or systemic bioavailability compared with the oral tablet. (Source: Drugs in R&D)
Source: Drugs in R&D - June 1, 2018 Category: Drugs & Pharmacology Source Type: research
Correction to: The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future
In the original publication, the name of the author in T. (Source: Drugs in R&D)
Source: Drugs in R&D - June 1, 2018 Category: Drugs & Pharmacology Source Type: research
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study
In the Original Publication of the article, In Introduction part, 7th line, the value “5-100nM” has been published incorrectly. The correct value should read as “Plasma concentration of 50-100ng/ml”. In the Original Publication of the article, page 591, Table 2 has been published incorrectly. The corrected table is shown in the following page (Source: Drugs in R&D)
Source: Drugs in R&D - June 1, 2018 Category: Drugs & Pharmacology Source Type: research
